|
||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
-Aminobutyric Acid Receptors Differentially Modulate Calcium Currents in Retinal Ganglion Cells
,
Department of Physiology, and
Department of Ophthalmology, School of Medicine, State University of New York, Buffalo, New York 14214
| ABSTRACT |
|---|
|
|
|---|
-aminobutyric acid (GABA) receptors were studied in amphibian retinal ganglion cells using whole cell current and voltage clamp techniques. The aim was to identify the types of receptor present and their mechanisms of action and modulation. Previous results indicated that ganglion cells possess two ionotropic GABA receptors: GABAAR and GABACR. This study demonstrates that they also possess two types of metabotropic GABAB receptor: one sensitive to baclofen and another to cis-aminocrotonic acid (CACA). The effects of these selective agonists were blocked by GDP-β-S. Baclofen suppressed an
-conotoxin–GVIA-sensitive barium current, and this action was reversed by prepulse facilitation, indicative of a direct G-protein pathway. The effect of baclofen was also partially occluded by agents that influence the protein kinase A (PKA) pathway. But the effect of PKA activation was unaffected by prepulse facilitation, indicating PKA acted through a parallel pathway. Calmodulin antagonists reduced the action of baclofen, whereas inhibitors of calmodulin phosphatase enhanced it. Antagonists of internal calcium release, such as heparin and ruthenium red, did not affect the baclofen response. Thus, the baclofen-sensitive receptor may respond to influx of calcium. The CACA-sensitive GABA receptor reduced current through dihydropyridine-sensitive channels. Sodium nitroprusside and 8-bromo-cGMP enhanced the action of CACA, indicating that a nitric oxide system can up-regulate this receptor pathway. CACA-sensitive and baclofen-sensitive GABAB receptors reduced spike activity in ganglion cells. Overall, retinal ganglion cells possess four types of GABA receptor, two ionotropic and two metabotropic. Each has a unique electrogenic profile, providing a wide range of neural integration at the final stage of retinal information processing.
Key Words: baclofen cis -aminocrotonic acid calcium/calmodulin adenylate cyclase guanylate cyclase
| introduction |
|---|
|
|
|---|
-aminobutyric acid (GABA)1 receptors. It possesses a diversity of GABAA receptors (GABAAR) (Greferath et al., 1995
While a plethora of GABA receptors have been identified in retina, often they have been discretely localized to small groups of neurons. For example, in white perch retina the GABACR has been described in a rod-driven horizontal cell (H4) (Qian and Dowling, 1993
), while in catfish retina this receptor was found in cone-driven, but not rod-driven, horizontal cells (Dong et al., 1994
; Takahashi et al., 1994
). The baclofen-sensitive GABABR has been identified in fish ganglion cells but was not seen in fish horizontal or bipolar cells (Bindokas and Ishida, 1991
). In one type of goldfish bipolar cell a cis -aminocrotonic acid (CACA)-sensitive, but not the baclofen-sensitive, GABA receptor was detected (Matthews et al., 1994
). This restricted expression fits a model in which GABARs are precisely localized so that each receptor subtype is associated with particular neurons. The implication is that there is a functional correlation between receptor properties, such as conductance and kinetics, and the physiology of the neuron. In this context, Pan and Lipton (1995)
reported that the GABACR found in rat bipolar cells produced a smaller and slower current than the GABAAR. It is tempting to conclude that there is a good match between this receptor and the relatively slow and small responses of the rod pathway.
An alternative model of GABA receptor diversity is that multiple GABARs may be localized in one cell and thereby expand the inhibitory capability of that neuron. If present, this confluence of GABA receptor subtypes could be particularly important in retinal ganglion cells, the recipients of powerful GABAergic input from amacrine cells and the final integrators of retinal information. Therefore, we examined retinal ganglion cells to determine their complement of GABA receptors. We previously reported that amphibian ganglion cells possess two types of ionotropic GABA receptor: GABAA and GABAC (Zhang and Slaughter, 1995
). We find that these neurons also contain two types of metabotropic GABA receptor, one sensitive to baclofen and the other to CACA. Thus, ganglion cells possess every type of GABA receptor currently identified. Through these different receptors, GABA regulates chloride and potassium conductances and modulates voltage-dependent calcium conductances. This permits a graded level of inhibition by parallel deployment of different conductance mechanisms. The GABA receptors can be differentially modulated by the internal or external environment of the ganglion cell, indicating that the balance of receptor inhibition can be tuned.
| materials and methods |
|---|
|
|
|---|
) were used to form gigaseals. Recordings were obtained from neurons in the ganglion cell layer, a somatic layer that Lukasiewicz and Werblin (1988)
A few experiments were performed on isolated ganglion cells. A similar dissection procedure and standard dissociation procedures were employed, as detailed previously (Pan and Slaughter, 1995
).
Whole cell pipette solution consisted of (in mM): 106 K-gluconate, 5 NaCl, 2 MgCl2, 5 EGTA, and 5 HEPES, buffered to pH 7.4 with KOH. To reduce calcium channel run-down, the pipette solution also contained an "ATP-regenerating cocktail" consisting of 4 mM ATP, 20 mM phosphocreatine, and 50 U/ml creatine phosphokinase. In experiments to study the CACA-sensitive GABA receptor, the ATP-regenerating system was replaced with 4 mM ATP and 0.3 mM GTP. At the recommendation of one reviewer, a few experiments were performed using nystatin perforated patches. In these cases, the same internal solution was used without the ATP-regenerating medium.
Both voltage steps and ramps were used to evoke currents. Since the barium currents that we measured were sustained and showed very little inactivation over this time course, we found that results using the step and ramp were similar. For convenience, ramp data were most often obtained. The figures in this paper display the original data and are not corrected for electrode tip potential or series resistance. The cells had high input resistances so leak subtraction was not necessary. The tip potential was measured for each pipette solution (Neher, 1992
), and the correction factor is mentioned in RESULTS, particularly where reversal potential measurements are presented. The amplifier did not have series resistance compensation. Except for perforated patch recordings, access resistance was generally between 6 and 15 M
. This resulted in an offset in the peak barium currents. However, since we were monitoring sustained currents and examining these currents over a wide range of potentials, this offset did not significantly influence our results. In a few cases, where a large shift occurred, the data were discarded. When both tip potential and series resistance voltage offsets were subtracted, the barium current was calculated to peak near +10 mV. This information was not a topic of this paper, so these calculations were not routinely done for each cell and the raw data is shown without these corrections. Voltage clamp experiments were performed using an Axoclamp 2A amplifier in continuous voltage clamp mode and PCLAMP software on a Gateway 486 computer equipped with a Labmaster A/D board. Analysis was performed employing PCLAMP, EXCEL, and Origin software.
Control amphibian Ringer's solution consisted of (in mM): 111 NaCl, 2.5 KCl, 1.8 CaCl2, 1 MgCl2, 10 dextrose, and HEPES buffered to pH 7.8 and oxygenated. When calcium currents were studied in isolation, 10 mM BaCl2 and 40 mM tetraethyl ammonium chloride (TEA·Cl) replaced equimolar NaCl in the extracellular medium. Tetrodotoxin (1 µM) was used to block sodium currents. Application of 25 µM CdCl2 suppressed most of the inward current under these conditions, indicating that most, if not all, of the observed current arose from calcium channels. Control and drug containing solutions were applied through a gravity fed system to a manifold in connection with the perfusion chamber containing the retinal slice. Valves controlled drug application, and there was a delay of
10 s due to exchange time of the system. Alternatively, drugs were applied through a puff pipette positioned at the edge of the retina near the cell of interest. In this case, Ringer's solution was still constantly applied to the retinal slice. When antagonists were tested, they were applied first, then after 30–60 s agonist was applied with antagonist. Generally, one cell was recorded in each retinal slice to avoid residual drug effects. Drug effects described in this paper are steady-state values, usually obtained 30–60 s after drug application.
The drug concentrations required to evoke effects in the slice preparation were often higher than anticipated, indicating that there was a diffusion or uptake barrier. For example, 100 µM GABA had only a small effect in the slice preparation, although it produced a near maximal effect when applied to isolated ganglion cells (Pan and Slaughter, 1995
). This was true for glutamate as well (Shen and Slaughter, unpublished observations). Therefore, there is probably a disparity between the dose applied and the effective drug concentration at the receptor. This phenomenon has been noted in retinal slice studies from other laboratories. Also, during the course of these studies we noted a decrease in the response to baclofen and to cis -aminocrotonic acid. Whether this represented a seasonal change or other effect was unclear. A series of initial experiments were performed using 100 µM baclofen, later 50 µM baclofen was used. In RESULTS, the average effect of 100 µM baclofen is reported to be greater than the effect of 50 µM, but this is probably due to the time periods when the studies were completed. Some experiments compare the effects of second messenger antagonists with the average effect of 100 or 50 µM baclofen. These antagonist experiments were performed in periods that overlapped the experiments from which the average data were obtained, and therefore represent ganglion cell populations with appropriate control responses. In CACA experiments, 5 µM doses produced nearly 50% suppression in early experiments (winter), but only about 20% suppression in later experiments (summer). Again, this may have been due to seasonal changes or other factors. When comparing data between experiments, we only contrasted effects measured at the same time period (usually the same day or week). All statistical data are presented as means ± SEMs.
SR95531, 2-hydroxysaclofen, nifedipine, nimodipine, trifluoperazine, KN-62, forskolin, H-9, Rp-cAMP, microcystin, calmidazolium, ruthenium red, heparin, NG-monomethyl-L-arginine, and sodium nitroprusside were purchased from Research Biochemicals, Inc. (Natick, MA). CACA was obtained from Tocris Cookson (St. Louis, MO). Cyclosporin A was obtained from Calbiochem Corp. (San Diego, CA). CGP35348 and baclofen were gifts from Ciba-Geigy (Basel, Switzerland). All other chemicals were obtained from Sigma Chemical Co. (St. Louis, MO).
| results |
|---|
|
|
|---|
|
Receptor Modulation of Calcium Currents
In a number of systems, a baclofen-sensitive GABABR has been associated with the down-regulation of calcium currents. In retina, this has been reported in a subset of amphibian bipolar cells (Maguire et al., 1989
) and in goldfish ganglion cells (Bindokas and Ishida, 1991
). We therefore examined the effect of baclofen on calcium channel current in amphibian ganglion cells. The measurement of calcium channel current required a modified Ringer's solution, which contained 10 mM barium, 40 mM TEA-Cl, and was nominally calcium free. Under these conditions we observed an HVA, relatively sustained inward current that was blocked by 100 µM external cadmium (data not shown). In all these experiments, barium was the charge carrier. Since this current was relatively noninactivating, we found that similar data were obtained using either voltage steps or ramps.
Baclofen suppressed a portion of the HVA barium current in ganglion cells (Fig. 2). The neuron was held at –70 mV, stepped to –120 mV, and then the voltage was ramped to +60 mV in 1 s. This paradigm evoked an inward barium current (Fig. 2 A1) that was suppressed approximately 30% by 100 µM baclofen (Fig. 2 A2). Adding 2-hydroxysaclofen (1 mM), an antagonist of baclofen-sensitive GABA receptors (Kerr et al., 1988
), restored the inward current close to its control value (Fig. 2 A3). The lower three panels, taken from recordings of another ganglion cell, show that picrotoxin, an antagonist of both GABAARs and GABACRs, did not block the effect of baclofen on the HVA barium current. In experiments on 73 cells, 50 µM baclofen reduced the HVA current by 29 ± 1% (mean ± SEM), while in another 22 ganglion cells 100 µM baclofen reduced the barium current by 40 ± 3% (see MATERIALS AND METHODS regarding this difference). In the presence of 100 µM picrotoxin, 100 µM baclofen reduced the barium current by 44 ± 3% (n = 6), indicating that picrotoxin did not reduce baclofen's action. This pharmacology leads to the conclusion that amphibian ganglion cells possess a baclofen-sensitive GABABR that can down-regulate HVA calcium currents.
|
To determine if ganglion cells possessed another GABA receptor, we applied GABA in the presence of antagonists of the GABAAR, GABACR, and the baclofen-sensitive GABABR. Since 2-hydroxysaclofen is a weak and competitive antagonist of baclofen-sensitive GABABRs, we sometimes chose to saturate the baclofen-sensitive receptor instead of blocking it. When GABA was applied in the presence of SR95531, picrotoxin, and baclofen, it was still able to produce an additional suppression of the barium current (Fig. 3 A). In nine cells tested in this manner, GABA reduced the barium current by 11 ± 2%. Another GABAR has been identified in goldfish retina and shown to down-regulate HVA calcium channels in bipolar cells (Matthews et al., 1994
). This has been proposed as a novel type of GABABR. It can be identified pharmacologically by its sensitivity to low micromolar concentrations of CACA and its insensitivity to bicuculline, SR95531, picrotoxin, baclofen, or 2-hydroxysaclofen.
|
Since different internal solutions were used in recording baclofen-sensitive and CACA-sensitive currents, nystatin perforated patch recordings were used to compare the actions of baclofen, CACA, and GABA while limiting the effects of cell dialysis. High concentrations were used to produce maximal responses to each agonist (50 µM CACA, 100 µM baclofen, and 200 µM GABA). The retina slice was pretreated and continuously superfused with picrotoxin (200 µM) to avoid the effects on ionotropic GABA receptors. In five cells, baclofen was found to reduce the barium current by a mean of 28% (from a control value of 1,028 ± 169 pA to 708 ± 109 pA); CACA reduced the current by 9% (to 924 ± 135 pA); GABA reduced the current by 46% (to 534 ± 82 pA). The response to each agonist was statistically significant (P < 0.05, Wilcoxin's signed-ranks test).
The ionotropic GABACR is sometimes referred to as CACA-sensitive because CACA can be more effective at activating the GABACR than the GABAAR (Feigenspan et al., 1993
; Qian and Dowling, 1993
; Pan and Lipton, 1995
). We previously reported that high concentrations of CACA were needed to stimulate the GABACR, and these concentrations also activated the GABAAR (Zhang and Slaughter, 1995
). This is in contrast to the receptor identified in Fig. 3, which is sensitive to low micromolar concentrations of CACA. To avoid confusion with reports describing CACA sensitivity of the GABACR or GABAAR, we refer to this receptor as the CACA-sensitive GABABR (GABAB-CACAR).
Baclofen's Action on Different Types of Calcium Channels
Calcium channel blockers were employed to evaluate the characteristics of the currents regulated by baclofen or CACA. The left side of Fig. 4 shows examples of ramp-elicited barium currents in the presence of baclofen alone, the blocker alone, and the combination of baclofen with the channel blocker. 19 ganglion cells were used to test the effects of two L-type calcium channel blockers: nimodipine and nifedipine. The effect of 50 µM baclofen alone was tested in 14 of the 19 cells and found to reduce the barium current by 21 ± 2%. In the 19 cells, 50 µM nifedipine or nimodipine was applied. This is a concentration found to block baclofen's effect on L-type calcium channels in bipolar cells in the same preparation (Maguire et al., 1989
). These dihydropyridines reduced the barium current by 17 ± 2%. In the presence of nifedipine or nimodipine, baclofen reduced the calcium current in these 19 cells by an additional 22 ± 2%. Thus, baclofen produced approximately the same percent suppression of the calcium current whether the dihydropyridine channel blockers were present or not. If baclofen had no effect on the L-type calcium current, then the percentage suppression by baclofen should be greater in the presence of these blockers. That is, if these two effects were independent they should be additive. On average, the percent suppression by baclofen was slightly greater in the presence of the blockers, but this was not statistically significant. Since the blockers reduced the calcium current by 17% on average, an additive effect would only alter the percent suppression by baclofen from a mean suppression of 21% to a mean suppression of 25% (compared to the observed mean suppression of 22%). Therefore, we can conclude that baclofen does not act primarily on L-type channels, although we cannot exclude a small modulation of L-type calcium channels.
|
-conotoxin–GVIA, had a much larger effect on both the calcium current and baclofen's action (Fig. 4, bottom). In eight cells,
-conotoxin reduced the barium current by 57 ± 7%. In the presence of
-conotoxin, 50 µM baclofen produced only a 14 ± 3% suppression of the remaining reduced barium current. Of the eight cells used in these experiments, seven had been previously tested with baclofen alone. Baclofen had produced a mean barium current suppression of 37 ± 2%. If baclofen acted exclusively on non–N-type calcium channels, it would be expected to suppress 86% of the remaining calcium current in the presence of
-conotoxin. If
-conotoxin-GVIA is acting selectively, this indicates that a large fraction of the baclofen effect is on the N-type channel.
The CACA-sensitive GABAB Receptors Act on L-type Calcium Channels
In contrast to the effect of the GABAB-BACLOFENR, the GABAB-CACAR appears to act predominantly at the dihydropyridine-sensitive calcium channel (Fig. 5). The top row in this figure shows a recording from one ganglion cell in which 50 µM nimodipine reduced the voltage-activated barium current. In the presence of nimodipine, 5 µM CACA had little additional effect. After washout and recovery of the barium current, CACA alone was able to reduce the barium current. The reduction by CACA was similar to that produced by nimodipine. A summary of data is charted in the lower portion of Fig. 5. The CACA alone data in this chart are drawn from our initial study of nine ganglion cells in which 5 µM CACA suppressed a mean of 46 ± 5% of the barium current. In a different set of ten ganglion cells, 50 µM nimodipine reduced the barium current by 25 ± 3%. In these ten neurons, after nimodipine reduced the barium current, CACA in the presence of nimodipine produced an additional barium current reduction of 9 ± 3%. All recordings were performed with 0.3 mM GTP in the patch electrode.
|
|
|
Baclofen's Second Messenger Pathway
The effect of baclofen was reversed by prepulse facilitation. These experiments were performed in isolated cells. The protocol was to activate high voltage–activated calcium channels by depolarizing the cell to +10 mV, from a holding potential of –70 mV. Then the cell was prepulsed to +100 mV, then again clamped to +10 mV. Fig. 8 shows superimposed currents obtained under control conditions and in the presence of baclofen. High concentrations of baclofen were required to activate the GABA receptor in the isolated cell preparation. The reason for this is currently being investigated. However, the effects of baclofen in isolated cells were similar to those found in the slice, both in terms of pharmacology (2-hydroxysaclofen sensitivity) and electrogenic action. Under control conditions, the barium current was of similar magnitude before and after the prepulse. But, in the presence of baclofen, the barium current was much larger after the prepulse (arrows). The peak of the barium current in baclofen, after the prepulse, was similar to the magnitude of the barium current before baclofen application. Prepulse facilitation has been reported for a number of metabotropic transmitter systems, including the GABABR. It has been suggested the phenomenon is indicative of a direct G-protein modulation of the calcium channel (Boland and Bean, 1993
; Campbell et al., 1995
).
|
|
The effects of PKA agonists and antagonists suggest a role for this pathway in mediating the response to baclofen, whereas the prepulse data suggest a direct G-protein action that is independent of second messengers such as PKA. This discrepancy could be explained if the PKA system autonomously regulated the baclofen-sensitive calcium channel. Prepulse experiments supported this proposition (Fig. 10). While the effect of baclofen was reversed by prepulse facilitation (response 2 in Fig. 10), the action of forskolin was unaffected by the prepulse (response 3). In addition, the effect of baclofen and forskolin together (response 4) was less than the sum of each agent individually. This indicates that baclofen and forskolin act in parallel to reduce the calcium channel activation. Forskolin acts by a mechanism that differs from that produced by GABAB-BACLOFENR activation, yet occludes the effect of baclofen.
|
|
We did not find any evidence that the calcium-calmodulin modulation of the GABABR pathway resulted from calcium release from internal stores. Neither heparin, a blocker of the IP3 pathway, nor ruthenium red, a blocker of the ryanodine receptor, reduced the effect of baclofen (Fig. 11, D and E). Ruthenium red was tested by placing it in the electrode because extracellular application significantly reduced membrane barium currents. In three cells, 50 µM baclofen in the presence of ruthenium red reduced the barium current by 30 ± 5%. Heparin was also included in the patch pipette solution. After heparin dialysis, 50 µM baclofen still reduced the barium current by 33 ± 1% (n = 7). This suppression by 50 µM baclofen, in the presence of ruthenium red or heparin is very similar to the average effect of 50 µM baclofen alone (29 ± 1% suppression).
Modulation of CACA-sensitive GABAB Receptors
As noted, internal levels of GTP regulate the CACA-sensitive GABABR. Associated with this observation, GABAB-CACAR activation was significantly (P < 0.01) enhanced by sodium nitroprusside or by 8-bromo-cyclic GMP, as illustrated in Fig. 12. In these experiments, a voltage ramp was applied every 30 s and the peak inward barium current was measured. When 50 µM 8-bromo- cyclic GMP was superfused on the retinal slice (Fig. 12 A), it produced a modest reduction in the barium current. In the presence of 8-bromo-cGMP, 50 µM CACA produced a large reduction in the HVA barium current. After recovery, CACA alone was applied and caused a smaller reduction in the barium current. In ten cells, CACA in the presence of 8-bromo-cGMP reduced the barium current by 38 ± 4%, while CACA alone suppressed 12 ± 2% of this current. The same experiment was performed in the presence of 20 µM H-9, a blocker of guanylate kinase. Under these conditions the effect of CACA was not enhanced by 8-bromo-cGMP (Fig. 12 B). In ten cells, CACA alone suppressed 15 ± 3% of the barium current, but in the presence of H-9 and 8-bromo-cGMP only 11 ± 3% of the current was suppressed. As another control, the retina was superfused with membrane impermeant 100 µM cGMP. It did not enhance the effect of CACA in any of 16 cells tested. When the retina was superfused with 300 µM sodium nitroprusside, a generator of NO, it also produced a modest suppression of the peak calcium current and it enhanced the effect of CACA (Fig. 12 D). In seven cells, CACA alone produced a 6 ± 1% calcium current suppression, while in the presence of sodium nitroprusside CACA suppressed 21 ± 6% of the calcium current. NG-monomethyl-L-arginine, an inhibitor of nitric oxide synthase, was tested in four ganglion cells, but alone it did not suppress the effect of CACA (data not shown). These results indicate that nitric oxide stimulation of cGMP can up-regulate the CACA-sensitive GABA receptor, but that the NO system is not endogenously active under the conditions of our experiments.
|
| discussion |
|---|
|
|
|---|
Modulation of the GABAB-BACLOFENR Transduction Pathway
The action of GDP-β-S indicates that the GABAB-BACLOFENR acts through a G-protein pathway (Fig. 7), and prepulse experiments suggest that a G-protein subunit may directly modulate the calcium channel (Boland and Bean, 1993
). Forskolin and internal cAMP reduced the effect of baclofen, but even relatively high doses of these agents did not eliminate baclofen's effect. Moreover, the effect of baclofen was reversed by prepulse facilitation while forskolin's action was unaltered by this protocol. Therefore, it is likely that PKA activates a second, parallel pathway that independently down-regulates the same channels affected by baclofen.
Blocking of calcium-calmodulin with calmidazolium, trifluoperazine, or W-7 largely suppressed GABAB-BACLOFENR action. None of these agents alone produced an obvious alteration in the calcium current. Subtle changes would be difficult to detect because all drugs were applied by internal dialysis and therefore were compared statistically to other neurons that served as a control. Calcium-calmodulin stimulates a number of pathways, including specific phosphatases and kinases. KN-62, a potent blocker of some calcium-calmodulin kinases, did not suppress the effect of baclofen. Blockers of calcium-calmodulin dependent phosphatases, such as cyclosporin A and microcystin, enhanced the effect of baclofen. Phosphatase inhibitors did not appear to have a direct effect on the calcium current, indicating that phosphorylation enhanced the GABAB-BACLOFENR pathway.
Thus, calmodulin-dependent phosphatases down-regulated the GABAB-BACLOFENR. But calmodulin antagonists reduced the effect of baclofen, indicating that calmodulin stimulation is required for GABAB-BACLOFENR activity. Therefore, another calmodulin pathway must be involved, possibly a calmodulin-dependent kinase. The ineffectiveness of KN-62 prevents clear identification of a calmodulin kinase, but the action of H-7 (coupled with the ineffectiveness of Rp-cAMP) could be interpreted as a block of a calmodulin-kinase pathway. While the precise calmodulin kinase pathway was not identified, these experiments suggest a regulatory scheme In which calmodulin modulates the activity of the GABA receptor by both up-regulation through kinase activation and down-regulation through phosphatase activation.
A tentative model of GABAB-BACLOFENR transduction consistent with our data (Fig. 13) proposes that baclofen down-regulates N-type calcium channels through a direct G-protein pathway. The GABAB-BACLOFENR is biphasically modulated by calmodulin: up-regulation of the receptor by calmodulin, probably through a kinase, and down-regulation through a calmodulin-dependent phosphatase. The balance between these two calmodulin-dependent enzymes would determine the phosphorylation state, and therefore the activity, of this transduction pathway. In addition, a parallel PKA pathway also down-regulates the same population of calcium channels.
|
Modulation of GABAB-CACAR Action
Considering the variety of GABA receptors in ganglion cells, changes in the weighting between different receptors can serve to alter the postsynaptic response to the same presynaptic GABAergic inputs. Second messengers can modulate each GABA receptor. We found that internal dialysis with ATP or GTP shifted the relative effectiveness of the GABAB-BACLOFENR and GABAB-CACAR, respectively. Related to this effect, 8-bromo-cGMP or sodium nitroprusside augmented the effects of CACA application. This implies that NO stimulation of guanylate cyclase can enhance the effectiveness of the GABAB-CACAR-activated second messenger cascade. However, NO antagonists alone did not decrease the effect of CACA, indicating that NO production was normally low under the conditions of our experiments. Liepe et al. (1994)
found that many cells in the tiger salamander retina have the ability to synthesis NO. Amacrine, ganglion, and Müller cells all have this capability and are positioned to affect the ganglion cell GABAB-CACAR.
Many regulatory mechanisms also produce differential effects on ionotropic GABARs. For example, protein kinase C reduces GABACR and enhances GABAAR currents (Dong and Werblin, 1994
; Feigenspan and Bormann, 1994
; Wellis and Werblin, 1995
). Similarly, low micromolar concentrations of zinc can reduce the GABACR current but enhance the GABAAR current (Chappell et al., 1995
). Zinc is believed to be synaptically released by photoreceptors (Wu et al., 1993
). Overall, these modulatory mechanisms can be employed to adjust the balance of inhibitory action produced by the four GABA receptor subtypes and suggests that the effects of the ionotropic receptors are complementary, as are the metabotropic receptors.
In summary, the range of GABA receptors found on ganglion cells coupled with the ability to modulate their effects extends the processing capabilities at this final step in the retinal network. Modulation of inhibition can be a mechanism to shift the balance of weighted inputs or postsynaptic processing in the retina's output neurons.
Dr. Jian Zhang's present address is Department of Ophthalmology and Visual Science, University of Texas Medical Center, Houston, TX 77030.
1 Abbreviations used in this paper: CACA, cis-aminocrotonic acid; GABA,
-aminobutyric acid; GDP-β-S, guanosine 5'-O-(2-thiodiphosphate); HVA, high voltage–activated. | ACKNOWLEDGMENTS |
|---|
Submitted: 6 December 1996
Accepted: 15 April 1997
| references |
|---|
|
|
|---|
-amino- butyric acid (GABA)
1 cDNA: a GABA receptor subunit highly expressed in the retina, Proc Natl Acad Sci USA, 1991, 88, 2673–2677.This article has been cited by other articles:
![]() |
M. Hou, L. Duan, and M. M. Slaughter Synaptic inhibition by glycine acting at a metabotropic receptor in tiger salamander retina J. Physiol., June 15, 2008; 586(12): 2913 - 2926. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. H. Chang, V. C. Kotak, and D. H. Sanes Long-Term Depression of Synaptic Inhibition Is Expressed Postsynaptically in the Developing Auditory System J Neurophysiol, September 1, 2003; 90(3): 1479 - 1488. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Vaquero, A. Pignatelli, G. J. Partida, and A. T. Ishida A Dopamine- and Protein Kinase A-Dependent Mechanism for Network Adaptation in Retinal Ganglion Cells J. Neurosci., November 1, 2001; 21(21): 8624 - 8635. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shen and M. M Slaughter Multireceptor GABAergic regulation of synaptic communication in amphibian retina J. Physiol., January 1, 2001; 530(1): 55 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. N. Behar, A. E. Schaffner, C. A. Scott, C. L. Greene, and J. L. Barker GABA Receptor Antagonists Modulate Postmitotic Cell Migration in Slice Cultures of Embryonic Rat Cortex Cereb Cortex, September 1, 2000; 10(9): 899 - 909. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Sherry and E. Townes-Anderson Rapid Glutamatergic Alterations in the Neural Retina Induced by Retinal Detachment Invest. Ophthalmol. Vis. Sci., August 1, 2000; 41(9): 2779 - 2790. [Abstract] [Full Text] |
||||
![]() |
K. Hirooka, D. E. Kourennyi, and S. Barnes Calcium Channel Activation Facilitated by Nitric Oxide in Retinal Ganglion Cells J Neurophysiol, January 1, 2000; 83(1): 198 - 206. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z.-H. Pan Differential Expression of High- and Two Types of Low-Voltage-Activated Calcium Currents in Rod and Cone Bipolar Cells of the Rat Retina J Neurophysiol, January 1, 2000; 83(1): 513 - 527. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shen and M. M. Slaughter Internal Calcium Modulates Apparent Affinity of Metabotropic GABA Receptors J Neurophysiol, December 1, 1999; 82(6): 3298 - 3306. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shen and M. M Slaughter Metabotropic GABA receptors facilitate L-type and inhibit N-type calcium channels in single salamander retinal neurons J. Physiol., May 1, 1999; 516(3): 711 - 718. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Kawai and P. Sterling AMPA Receptor Activates a G-Protein that Suppresses a cGMP-Gated Current J. Neurosci., April 15, 1999; 19(8): 2954 - 2959. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, N. Tian, and M. M. Slaughter Neuronal Discriminator Formed by Metabotropic gamma -Aminobutyric Acid Receptors J Neurophysiol, December 1, 1998; 80(6): 3365 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Gao and S. M. Wu Characterization of Spontaneous Inhibitory Synaptic Currents in Salamander Retinal Ganglion Cells J Neurophysiol, October 1, 1998; 80(4): 1752 - 1764. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Akopian, R. Gabriel, and P. Witkovsky Calcium Released From Intracellular Stores Inhibits GABAA-Mediated Currents in Ganglion Cells of the Turtle Retina J Neurophysiol, September 1, 1998; 80(3): 1105 - 1115. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Shen and M. M Slaughter Metabotropic and ionotropic glutamate receptors regulate calcium channel currents in salamander retinal ganglion cells J. Physiol., August 1, 1998; 510(3): 815 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. C. Kotak, S. Korada, I. R. Schwartz, and D. H. Sanes A Developmental Shift from GABAergic to Glycinergic Transmission in the Central Auditory System J. Neurosci., June 15, 1998; 18(12): 4646 - 4655. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|